Scinai Immunotherapeutics Ltd. SCNI
legal and commercial name is BiondVax Pharmaceuticals Ltd. We are a company limited by shares organized under the laws of Israel. We
shares on the Tel Aviv Stock Exchange (TASE), and we voluntarily delisted from the TASE in January 2018. In May 2015 we completed an
initial public offering of ADSs and ADSs warrants (which have since expired) on the Nasdaq Capital Market.
principal executive offices are located at Jerusalem BioPark, 2nd floor, Hadassah Ein Kerem Campus, Jerusalem, Israel, and
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $658.0K | — | — | — | — | — | — | — |
| Cost of revenue | $4.0M | $1.2M | — | — | — | — | — | — | — |
| Gross profit | -$2.7M | -$580.0K | — | — | — | — | — | — | — |
| R&D | $2.4M | $5.5M | $5.2M | $5.8M | $3.2M | — | — | — | — |
| SG&A | $2.5M | $2.5M | $4.5M | $5.3M | $7.6M | — | — | — | — |
| Total operating expenses | $4.9M | $8.1M | $9.7M | $11.1M | $10.9M | — | — | — | — |
| Operating income | -$7.5M | -$8.6M | -$9.7M | -$11.1M | -$10.9M | — | — | — | — |
| Interest expense | — | — | $343.0K | $351.0K | $336.0K | — | — | — | — |
| Net income | -$8.3M | $4.8M | -$6.5M | -$5.8M | -$8.2M | -$1.4M | — | — | -$10.0M |
| EPS, basic | — | — | 0.00 | 0.01 | -0.02 | — | — | — | — |
| EPS, diluted | — | — | 0.00 | 0.01 | -0.02 | — | — | — | — |
| Shares, diluted (wtd. avg.) | 9.34B | 3.23B | 1.56B | 754.1M | 564.6M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.7M | $2.0M | $4.9M | $14.2M | $17.5M | $3.1M | — | — | — |
| Receivables | $73.0K | $83.0K | — | — | — | — | $4.4M | — | — |
| Total current assets | $2.1M | $2.4M | $5.4M | $14.4M | $17.8M | — | — | — | — |
| Property, plant and equipment | $7.8M | $9.2M | $10.8M | $11.2M | $12.4M | — | — | — | — |
| Total assets | $11.6M | $13.4M | $17.5M | $27.1M | $32.0M | $17.7M | — | — | $23.6M |
| Short-term debt | — | — | — | $382.0K | $375.0K | — | — | — | — |
| Total current liabilities | $1.6M | $1.8M | $1.8M | $2.3M | $2.4M | — | — | — | — |
| Retained earnings | -$125.8M | -$117.5M | -$122.3M | -$115.8M | -$110.0M | — | — | — | — |
| Total equity | $8.1M | $10.0M | -$4.6M | -$1.8M | $982.0K | -$15.0M | — | — | $16.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.0M | -$6.3M | -$9.4M | -$7.3M | -$7.4M | — | — | — | — |
| Depreciation and amortisation | $1.4M | $1.6M | $514.0K | $562.0K | $471.0K | — | — | — | — |
| Stock-based compensation | $303.0K | $682.0K | $1.1M | $1.6M | $2.8M | — | — | — | — |
| Capital expenditure | $24.0K | $12.0K | $637.0K | $836.0K | $139.0K | — | — | — | — |
| Investing cash flow | -$24.0K | -$12.0K | -$637.0K | -$836.0K | -$139.0K | — | — | — | — |
| Financing cash flow | $5.8M | $3.4M | $1.1M | $6.8M | $21.4M | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-038011.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $658.0K | $1.3M |
| Gross profit | — | — | — | — | — | — | — | -$580.0K | -$2.7M |
| Net income | -$10.0M | — | — | -$1.4M | -$8.2M | -$5.8M | -$6.5M | $4.8M | -$8.3M |
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |